Published in Cancer Weekly, February 7th, 2012
"The results revealed that COLO 16 cells were resistant to 15 mu m ATRA treatment. FABP5 as well as the elements...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.